Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.

Increased demands from an aging population and pandemic-related supply shortages leave provinces scrambling to allocate ...

The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the market ...

A disease historically associated with malnourishment on sailing vessels may have a new, modern culprit: Bariatric surgery.

Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.